ArticleThe British journal of general practice : the journal of the Royal College of General Practitioners2025
GPs' perspectives on GLP-1RAs for obesity management: a qualitative study in England.
Article in The British journal of general practice : the journal of the Royal College of General Practitioners, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.Scandinavian journal of primary health care · 2026Article
- Attitudes Toward Injectable GLP-1 Drugs for Obesity Treatment: A Qualitative Interview Study With Healthcare Professionals.Obesity science & practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective treatments are needed for the increasing number of people living with obesity. GPs are key in managing obesity within the NHS but report low confidence in available treatment options. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in weight management, but at the time of this study lacked commissioned primary care service pathways for this indication.
aimTo explore the perspectives of NHS GPs in England on GLP-1RAs and their integration into primary care for weight management. DESIGN AND
settingIn this qualitative study, participants were GPs practising in England, recruited through purposive sampling to reflect diverse geographical and socioeconomic contexts.
methodTwenty-five semi-structured interviews, which were conducted April-July 2024, were thematically analysed.
resultsParticipants generally held positive views about the implementation of GLP-1RAs for weight management in primary care; however, this was joined by hesitations about resource limitations. Navigating consultations with patients asking for prescriptions, or support with private use, often posed difficulties. Concerns included that GLP-1RAs could detract from tackling the broader determinants of obesity. Participants also worried that the medications could be misused, ultimately becoming an overly simplistic solution for patients, practitioners, and the wider health system.
conclusionOur findings suggest that while GPs view GLP-1RA integration as a valuable therapeutic option for primary care obesity management, they have concerns about this being done well. To strengthen GP support for implementation, it is essential to recognise the need for adequate resources and ensure that GLP-1RAs are integrated into a holistic strategy for addressing obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.